Multiple glioblastomas (GBMs) are aggressive, malignant, and sporadic brain tumors. We present the case of a 58-year-old patient with two GBMs in the right frontal lobe and associated edema. The patient presented with sudden left limb weakness accompanied by abnormal gait for five consecutive days. Magnetic resonance-guided laser interstitial thermal therapy (MRg-LITT), a minimally invasive technique that disperses thermal energy was used to cauterize the deep-seated brain lesions. Following two sessions of MRg-LITT, the patient showed full remission from symptoms. However, the disruption of the blood-brain barrier (BBB) induced vasogenic edema surrounding the necrotic GBMs. Post-operative nine-month MRI images revealed severe vasogenic edema and compression on the ventricles, shifting the midline toward the left side. Therefore the patient underwent an emergency craniectomy and continues to live with close follow-ups. Here, we established that LITT procedures were effective in cauterizing GBMs with no recurrence.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11392511 | PMC |
http://dx.doi.org/10.7759/cureus.66726 | DOI Listing |
Cureus
December 2024
Neurological Surgery, Upstate University Hospital, Syracuse, USA.
Over the past two decades, despite the emergence of various novel therapies for glioblastoma, patient survival outcomes remain poor, particularly in the recurrent stage of the disease. Cesium-131 (Cs-131) brachytherapy presents a promising treatment option for patients with newly diagnosed and recurrent brain neoplasms, enabling the initiation of radiation therapy at the time of tumor resection. This approach eliminates the typical delay in therapy following surgery and the need for multiple return visits for fractionated external beam radiotherapy.
View Article and Find Full Text PDFTransl Oncol
January 2025
Tango Therapeutics, Tango Therapeutics, 201 Brookline Avenue, Boston, 02215, MA, United States.
TNG908 is a clinical stage PRMT5 inhibitor with an MTA-cooperative binding mechanism designed to leverage the synthetic lethal interaction between PRMT5 inhibition and MTAP deletion. MTAP deletion occurs in 10-15 % of all human cancer representing multiple histologies. MTA is a negative regulator of PRMT5 that accumulates as a result of MTAP deletion.
View Article and Find Full Text PDFSci Rep
January 2025
Department of Stereotactic and Functional Neurosurgery, University Hospital of Bonn, 53127, Bonn, Germany.
Despite the favorable effects of immunotherapies in multiple types of cancers, its complete success in CNS malignancies remains challenging. Recently, a successful clinical trial of cytokine-induced killer (CIK) cell immunotherapy in patients with glioblastoma (GBM) has opened a new avenue for adoptive cellular immunotherapies in CNS malignancies. Prompt from these findings, herein, we investigated whether dendritic cells (DC) in combination with cytokine-induced killer cells (DC-CIK) could also provide an alternative and more effective way to improve the efficacy of GBM treatment.
View Article and Find Full Text PDFClin Chem
January 2025
Broad Institute of MIT and Harvard, Cambridge, MA, United States.
Background: Minimally invasive molecular profiling using cell-free DNA (cfDNA) is increasingly important to the management of cancer patients; however, low sensitivity remains a major limitation, particularly for brain tumor patients. Transiently attenuating cfDNA clearance from the body-thereby, allowing more cfDNA to be sampled-has been proposed to improve the performance of liquid biopsy diagnostics. However, there is a paucity of clinical data on the effect of higher cfDNA recovery.
View Article and Find Full Text PDFFront Neurol
December 2024
Precision Medicine Laboratory, Sub-Direction of Research Unit, INCan, Mexico City, Mexico.
Background: This systematic review and meta-analysis investigated the relationship between somatic oncogenic variants and prognosis, specifically with overall survival (OS) and progression-free survival (PFS) in patients diagnosed with supratentorial glioblastoma.
Methods: We included longitudinal studies and clinical trials involving a minimum of 40 adult participants diagnosed with supratentorial glioblastoma, wherein the status of variants was assessed. We conducted searches in multiple databases.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!